Article
Forbes Books Press Release Official
Why Comprehensive Testing Matters - Ken Schlosser’s Lung Cancer Story
Clips
Summary
Biomarker testing helped Ken Schlosser live with stage IV lung cancer for over 6 years. Here's how it shaped his care plan from the start.
A Real Story of Hope, Testing, and Targeted Care.
In this episode of Labcorp Perspectives: Oncology, host Dr. Rebecca Previs speaks with Ken Schlosser about how biomarker testing informed his care plan after a stage IV lung cancer diagnosis in 2019.
Ken shares how a routine trip to the ER led to the discovery of an ALK+ alteration, and how comprehensive genomic profiling through OmniSeq helped guide a treatment path that has kept him thriving for more than six years.
They also discuss the role of patient education and advocacy in expanding access to precision testing, as well as why understanding your biomarker status can make a significant difference in care outcomes.
This episode offers an inspiring look at how data-driven decisions can transform lives and why testing is crucial from the outset.
Related Topics
You May Also Like
Forbes Books Press Release Official
Article
Envision Pharma Group
AI-powered real-world evidence: Strategically enhancing value and access
Article
Envision Pharma Group
Patient involvement: A must-have in medicine development, but is it being overlooked in a cost-constrained environment?
Article
Neil Carleton and Priscilla F. McAuliffe
Are the chronological age cutoffs used in clinical oncology guidelines biologically meaningful?
Article
Timothy Qi, Tyler Dunlap, Yanguang Cao1
Embracing Project Optimus: Can we Leverage Evolutionary Theory to Optimize Dosing in Oncology?
Article
Jayson L. Parker, Sebnem S. Kuzulugil, Kirill Pereverzev, Stephen Mac, Gilberto Lopes, Zain Shah, Ashini Weerasinghe, Daniel Rubinger, Adam Falconi, Ayse Bener, Bora Caglayan, Rohan Tangri, Nicholas Mitsakakis